Haven't lost any weight on Wegovy? Work through these steps first

Step 1: Check which dose you're actually on

The most common reason people see no weight change early in Wegovy treatment is straightforward: they haven't reached a therapeutic dose yet. The licensed schedule starts at 0.25 mg and steps up roughly every four weeks, 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg. The starting dose exists primarily to let your body adjust to the medicine and reduce nausea, not to produce meaningful weight loss. If you're in the first one or two dose steps, a lack of significant change on the scales is expected, not a failure.

This is a misconception worth letting go gently: many people assume any GLP-1 medicine should produce visible results from the first pen. The trial data in the STEP 1 study, published in the New England Journal of Medicine, measured outcomes over 68 weeks at the full 2.4 mg maintenance dose, a process that takes the best part of six months just to complete titration. If you've recently increased to 1.7 mg or 2.4 mg, give it a full four weeks before drawing conclusions.

Your prescriber can confirm exactly where you are in the schedule and whether the pace of titration is right for you. You can also explore how weight loss on Wegovy typically progresses by dose phase.

Step 2: Review the practical factors that blunt the medicine's effect

Semaglutide works by reducing appetite and slowing gastric emptying, but the degree of appetite suppression varies between people. If you're still eating roughly the same amount despite being on Wegovy, it's worth being honest with your prescriber about it, this isn't a character flaw, it's useful clinical information. Stress, sleep and certain other medicines can all counteract appetite signals.

Injection technique matters too. Semaglutide is injected subcutaneously, into the fat layer under the skin, not into muscle. Injecting into an area with insufficient fat, or into a site that has become hardened from repeated use, can reduce absorption. Rotating between the abdomen, thigh and upper arm each week is part of the guidance for a reason. The NHS patient information for semaglutide covers injection sites and storage requirements in detail, and it's worth re-reading if you haven't recently.

Storage is another practical point: Wegovy pens should be kept refrigerated between 2–8°C. A pen left at room temperature beyond the window described in the Patient Information Leaflet may deliver a degraded dose. If you've had any doubt about storage, mention it to your prescriber rather than continuing to assume the pen was fine.

Step 3: Know when inadequate response becomes a clinical conversation

NICE's recommendation for semaglutide (Wegovy) includes a clear checkpoint: if someone hasn't achieved at least 5% weight loss after six months at the maintenance dose, continuing treatment should be reviewed. That's a formal six-month window at full dose, not six months from the first injection. It's also a review, not an automatic stop; the prescriber considers the full clinical picture.

If you're well past the maintenance dose and genuinely seeing no movement, that conversation is worth having. There is real variation in response to GLP-1 medicines, and for some people a different treatment may suit them better. You can read more about why some people don't respond to semaglutide or look at what the upper end of Wegovy results looks like in practice. Either way, stopping without a clinical conversation means losing the chance to identify whether a practical fix or a dose adjustment might change the outcome.

If you're uncertain about the cost of continuing or restarting treatment, our Wegovy cost page sets out what private treatment typically involves, without hidden fees.

Step 4: Understand what your prescriber needs from you

A review of inadequate response is most useful when you can give your prescriber specifics: how long you've been at the current dose, your injection routine, any changes to diet or activity, other medicines you take, and your most recent weight. It also helps to know whether your starting BMI and any comorbidities align with the licensed criteria for Wegovy, a full overview of who Wegovy is licensed for in the UK is worth checking if you're unsure.

At nume, a named prescriber, not software, reviews every clinical query, the same day you raise it. If you'd like a fresh clinical perspective on whether your current treatment plan is right for you, speak to our prescribers to start the conversation. For broader context on how this medicine fits into weight management, the Wegovy overview page is a good place to start, and our clinical team's approach is explained on the clinical team page.